Latest Revenue Forecast News

SCX.ai Holdings Limited is set to raise $40 million through a fully underwritten IPO at $0.30 per share, aiming to scale its sovereign AI inferencing platform built on ASIC hardware within Australian data centres. The company targets the fast-growing AI IaaS market with a focus on secure, low-latency AI workloads.

Brazilian Rare Earths (ASX: BRE) has unveiled a scoping study for its Monte Alto and Camaçari project in Bahia, Brazil, showcasing ultra-high grades and robust economics with a post-tax NPV8 of US$6 billion and a rapid 1.1-year payback.

Synertec Corporation has affirmed that its recent announcements on a $4 million AGL contract and a 40-50% revenue growth forecast for FY27 were material and disclosed promptly, maintaining confidentiality until release.

FlexiRoam has landed a two-year master agreement with Etihad Airways to provide global connectivity for staff, aircraft data, and pilot iPads, reinforcing its enterprise growth strategy.

Vista Group International posted a 12% revenue increase in 1H26, driven by cloud adoption and marquee client wins, prompting an upgrade to its full-year revenue forecast.

Synertec has locked in a $4 million contract to upgrade AGL’s national SCADA system, reinforcing its foothold in critical infrastructure technology as it forecasts up to 50% revenue growth in FY27.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Axtec has secured a strategic partnership with MRI Software to integrate its full product suite into widely used Australian real estate software, opening a major distribution channel across agent networks nationwide.

Vinyl Group has expanded its media footprint through key acquisitions, boosting national audience reach and setting a clear path to profitability in FY27 with AI-driven Adaptive Media strategies.

IDT Australia boosts its FY26 revenue guidance to $16.8 million, anticipating a substantial narrowing of EBITDA losses to under $1 million, driven by strong demand and cost efficiencies.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

AFT Pharmaceuticals secures tentative FDA approval for Scomara cream to treat rare facial tumours but faces a US launch delay due to orphan drug exclusivity. The approval bolsters prospects in other markets where AFT expects competitive advantages.